Artiva Biotherapeutics, Inc. (ARTV)
NASDAQ: ARTV · Real-Time Price · USD
2.095
+0.015 (0.72%)
May 12, 2025, 11:06 AM - Market open
Artiva Biotherapeutics Stock Forecast
Stock Price Forecast
According to 6 professional analysts, the 12-month price target for Artiva Biotherapeutics stock ranges from a low of $18 to a high of $23. The average price target of $20 forecasts a 854.65% increase in the stock price over the next year.
Price Target: $20.00 (+854.65%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Apr 8, 2025.
Analyst Ratings
The average analyst rating for Artiva Biotherapeutics stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 4 | 4 | 4 | 4 |
| Buy | 2 | 2 | 2 | 3 | 3 | 3 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 6 | 7 | 7 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +997.85% | Apr 8, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $20 | Strong Buy | Reiterates | $20 | +854.65% | Mar 26, 2025 |
| Wedbush | Wedbush | Buy Reiterates $18 | Buy | Reiterates | $18 | +759.19% | Mar 25, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Maintains $23 → $20 | Buy | Maintains | $23 → $20 | +854.65% | Mar 25, 2025 |
| Needham | Needham | Strong Buy Reiterates $23 | Strong Buy | Reiterates | $23 | +997.85% | Mar 25, 2025 |
Financial Forecast
Revenue This Year
n/a
from 251.00K
Revenue Next Year
n/a
EPS This Year
-2.99
from -5.81
EPS Next Year
-2.90
from -2.99
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | n/a | n/a | n/a |
| Avg | n/a | n/a | n/a |
| Low | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | -2.74 | -2.24 | -1.79 |
| Avg | -2.99 | -2.90 | -2.91 |
| Low | -3.33 | -3.37 | -4.02 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | - | - |
| Avg | - | - | - |
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.